File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: 5-Hydroxytryptamine and vascular disease

Title5-Hydroxytryptamine and vascular disease
Authors
Issue Date1983
Citation
Federation Proceedings, 1983, v. 42 n. 2, p. 233-237 How to Cite?
AbstractThe release of 5-hydroxytryptamine (5-HT) from aggregating platelets may trigger acute vasospastic episodes of larger arteries, which can lead to tissue ischemia, particularly in the coronary and cerebral circulations. In hypertensive humans and animals, 5-HT may play a role in the maintenance of the chronic increase in peripheral resistance. This is suggested by the observations that 1) in several models of chronic hypertension there is a specific increase in the responsiveness of the blood vessel wall to the vasoconstrictor properties of 5-HT and a delayed tachyphylaxis to the monoamine; 2) the ability of hypertensive animals to clear 5-HT from the blood is reduced, and the platelets of hypertensive patients take up less 5-HT than those of normotensive humans; their activation to release 5-HT is accelerated; and 3) ketanserin, a 5-HT2-serotonergic antagonist devoid of agonistic properties, lowers arterial blood pressure in hypertensive humans and animals.
Persistent Identifierhttp://hdl.handle.net/10722/170696
ISSN
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorVanhoutte, PMen_US
dc.date.accessioned2012-10-30T06:10:30Z-
dc.date.available2012-10-30T06:10:30Z-
dc.date.issued1983en_US
dc.identifier.citationFederation Proceedings, 1983, v. 42 n. 2, p. 233-237en_US
dc.identifier.issn0014-9446en_US
dc.identifier.urihttp://hdl.handle.net/10722/170696-
dc.description.abstractThe release of 5-hydroxytryptamine (5-HT) from aggregating platelets may trigger acute vasospastic episodes of larger arteries, which can lead to tissue ischemia, particularly in the coronary and cerebral circulations. In hypertensive humans and animals, 5-HT may play a role in the maintenance of the chronic increase in peripheral resistance. This is suggested by the observations that 1) in several models of chronic hypertension there is a specific increase in the responsiveness of the blood vessel wall to the vasoconstrictor properties of 5-HT and a delayed tachyphylaxis to the monoamine; 2) the ability of hypertensive animals to clear 5-HT from the blood is reduced, and the platelets of hypertensive patients take up less 5-HT than those of normotensive humans; their activation to release 5-HT is accelerated; and 3) ketanserin, a 5-HT2-serotonergic antagonist devoid of agonistic properties, lowers arterial blood pressure in hypertensive humans and animals.en_US
dc.languageengen_US
dc.relation.ispartofFederation Proceedingsen_US
dc.subject.meshAnimalsen_US
dc.subject.meshConstriction, Pathologic - Physiopathologyen_US
dc.subject.meshHypertension - Physiopathologyen_US
dc.subject.meshKidney - Blood Supplyen_US
dc.subject.meshMonoamine Oxidase - Blooden_US
dc.subject.meshPlatelet Aggregationen_US
dc.subject.meshRatsen_US
dc.subject.meshRats, Inbred Strainsen_US
dc.subject.meshSerotonin - Pharmacology - Physiologyen_US
dc.subject.meshVascular Resistance - Drug Effectsen_US
dc.subject.meshVasoconstriction - Drug Effectsen_US
dc.title5-Hydroxytryptamine and vascular diseaseen_US
dc.typeArticleen_US
dc.identifier.emailVanHoutte, PM:vanhoutt@hku.hken_US
dc.identifier.authorityVanHoutte, PM=rp00238en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid6822294-
dc.identifier.scopuseid_2-s2.0-0020598963en_US
dc.identifier.volume42en_US
dc.identifier.issue2en_US
dc.identifier.spage233en_US
dc.identifier.epage237en_US
dc.identifier.isiWOS:A1983QB76100019-
dc.identifier.scopusauthoridVanHoutte, PM=7202304247en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats